Clinical Trial Update: Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection [Phase 2, Phase 3]

View source ↗

Summary

This entry notes a Phase 2/3 clinical trial evaluating capecitabine to prevent recurrence of hepatocellular carcinoma after curative resection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Capecitabine (capecitabine)

Snippet

Sponsor: Fudan University | Conditions: Hepatocellular Carcinoma, Neoplasm Metastasis | Phase 2, Phase 3 | Status: UNKNOWN